Sarah Cannon Promotes William Donnellan, MD, to Director, Leukemia/Myelodysplastic Syndrome Research
Posted on July 6, 2018
NASHVILLE, TENN., May 30, 2018 – Today, Sarah Cannon announced the promotion of William Donnellan, MD, to Director of Leukemia/Myelodysplastic Syndrome (MDS) Research in Nashville. Since joining Sarah Cannon in 2014, Dr. Donnellan has served as an investigator of hematologic malignancies, specializing in treating patients with a variety of blood cancers.
“Dr. Donnellan has played an integral role in advancing research for blood cancers and ensuring patients facing the disease are receiving the best possible care,” said David Spigel, MD, Chief Scientific Officer at Sarah Cannon. “Dr. Donnellan’s expertise and leadership in leukemia/MDS will continue to support our mission of finding more effective treatment options for patients in our communities.”
In his new role, Dr. Donnellan will oversee research surrounding myeloid stem cell disorders including myelodysplastic syndrome, acute myeloid leukemia and myeloproliferative neoplasms for the Sarah Cannon program in Nashville. The blood cancer program at TriStar Centennial is a part of a network of programs across Sarah Cannon – the Sarah Cannon Blood Cancer Network – upholding the highest levels of quality, infrastructure, research and care.
The Sarah Cannon Blood Cancer Network is one of the largest providers of hematopoietic cell transplantation (HCT), conducting more than 1,000 transplants annually through six FACT-accredited transplant centers. Dr. Donnellan will continue to serve in a leadership role for leukemia/MDS research across the Sarah Cannon Blood Cancer Network.
Dr. Donnellan received his undergraduate degree from Auburn University and his medical degree from the University of Alabama School of Medicine. He performed his internal medicine residency at the University of Alabama, Birmingham where he received the C. Glenn Cobbs Award for excellence at the Birmingham VA Medical Center and the Claude Bennett Award for outstanding performance at University Hospital. He then completed a fellowship in hematology/oncology at the University of Alabama, Birmingham with a special focus in blood and marrow transplantation.
Dr. Donnellan is board certified in internal medicine, hematology and medical oncology. Additionally, he is an associate with Tennessee Oncology, PLLC.
About Sarah Cannon Research Institute
Sarah Cannon Research Institute is the research arm of HCA Healthcare’s global cancer institute, Sarah Cannon. Focused on advancing therapies for patients, it is one of the world’s leading clinical research organizations conducting community-based clinical trials throughout the United States and United Kingdom. Sarah Cannon’s network of strategic sites includes more than 275 physicians who engage in research. The organization has led more than 300 first-in-man clinical trials since its inception in 1993, and has been a clinical trial leader in the majority of approved cancer therapies over the last 10 years. Additionally, Sarah Cannon offers management, regulatory, and other research support services for drug development and industry sponsors as well as strategic investigator sites through its contract research organization (CRO), Sarah Cannon Development Innovations. For more information, visit sarahcannon.com.